What do you make out of this? Sorry if it was posted before.

http://www.genengnews.com/gen-news-h...ates/81243879/

Roche is teaming up with Belgian firm reMynd to develop the latter’s preclinical-stage small molecule drug candidates targeting the α-synuclein and tau-related toxicities involved in Parkinson and Alzheimer diseases. reMynd claims the deal could be worth up to Euro 500,000 (about $636,000) in milestone payments from Roche, even before sales royalties.

The collaboration will involve the two firms establishing joint research teams, with Roche providing chemistry, lead-optimization, and preclinical development expertise, and reMynd carrying out nonclinical pharmacology studies and further research to unpick the underlying molecular mechanisms. Roche will take on all clinical development and worldwide commercialization of relevant products.

ReMynd claims its candidates are designed to inhibit the mechanisms of neurotoxicity involved in both these diseases, rather than just address the resulting symptoms. “Our most advanced compound in Parkinson’s disease has demonstrated full inhibition of disease progression in preclinical models and could be the first treatment in clinical development for Parkinson’s disease targeting α-synuclein-induced toxicity,” claims Gerard Griffioen, reMynd’s CSO. “Our Alzheimer’s tau program represents perhaps a greater potential as it addresses one of the most fundamental aspects of the disease,” adds Koen De Wite.

ReMynd is centered on the development of disease-modifying treatments against protein misfolding disorders, with a particular focus on Parkinson and Alzheimer diseases. The firm is exploiting its expertise both through the development of an in-house drug pipeline and through the provision of contract research services for evaluating the in vivo efficacy of experimental Alzheimer treatments using validated transgenic mouse models.

This is exactly the kind of news we are looking for...MJFF has been providing funding to ReMynd since 2009 in support of this potentially disease-modifying Parkinson's drug. Our funding is meant to help these nascent programs get sufficient data to get the attention of the deeper pockets--such as Roche. So this kind of hand-off is a big win. Roche's investment will enable this to move to the clinic.

MJFF has supported approximately 90 companies to date who are working to develop therapies that address the progression of Parkinson’s Disease (PD), treat symptoms and side effects, and develop critical tools such as biomarkers.

The potential new treatment targets the PD-implicated protein alpha-synuclein. Click here to read about MJFF's 2009 partnership with reMYND to drive critical dosing information on the target. http://www.michaeljfox.org/research_...s_3.cfm?ID=538

Debi

Dr Tiago Fleming Outeiro from the Instituto de Medicina Molecular in Lisbon, Portugal says yeast could be a powerful ally in the discovery of new therapeutic drugs to treat Parkinson's disease, a neurodegenerative disorder without any known cure.

The symptoms, which include rigidity, difficulty in initiating movements and resting tremors, are all related to the specific death of dopamine-producing neurons in the brain.

These neurons characteristically contain protein deposits, known as Lewy bodies. A small protein called alpha-synclein is the main component of these deposits.

Outeiro explains how baker's yeast, Saccharomyces cerevisiae, is helping researchers learn how alpha-synuclein might lead to Parkinson's disease.

"Yeast is a very simple but powerful model in which to study how alpha-synuclein actually works as, remarkably, many of the biochemical pathways involved are similar between yeast and humans," he said.

"There is still a lot we don't know about the function of this protein, but we do know that even small increases in the level of alpha-synuclein in cells lead to cell death," he added.

Dr Outeiro, along with colleagues in the USA, screened a library of 115,000 small compounds to try and identify those that are able to block the toxic effects of alpha-synuclein.

Several of these molecules have proved effective in preventing Parkinson's disease in worms and blocking alpha-synuclein toxicity in rat neurons. If developed further, they could form the basis of future drugs to treat Parkinson's disease in humans.

The work has been presented at the Society for General Microbiology's autumn meeting in Nottingham

Read more: Yeast offers clues to Parkinson's disease - The Times of India http://timesofindia.indiatimes.com/l...#ixzz0zFntxCZR